Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 10c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.53), $0.10 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $34.17 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• ArcelorMittal (MT:NA) (MT) PT Raised to EUR65 at Jefferies
• Exyn Technologies reports Q1 2026 results after Nasdaq IPO